GET DAILY SIGNALSAbCellera Biologics (ABCL) Delivers Q3 2026 Results with Key Clinical Validation
Key Takeaways
- AbCellera reported third-quarter 2026 total revenue of $10.6 million, up from $9.0 million in the same period a year earlier.
- Net loss narrowed to $40.8 million, or $0.13 per share, compared with a $57.1 million loss, or $0.19 per share, in Q3 2025.
- Results beat expectations: the loss per share came in better than the roughly $0.17 consensus, and revenue topped the roughly $6.2 million estimate.
- The quarter was headlined by positive Phase 2 data for ABCL635, the company's lead drug candidate for menopausal vasomotor symptoms (hot flashes).
- Following a $200 million share and pre-funded warrant offering, AbCellera ended the quarter with more than $790 million in cash and marketable securities and over $890 million in total liquidity.
- Management said it will not pursue further development of ABCL575 in atopic dermatitis after rival OX40-targeted programs were discontinued.
Earnings Context and Why It Matters
AbCellera Biologics (ABCL) has shifted its focus from partnered antibody discovery toward building its own pipeline of drug candidates, a transition that makes quarterly financials only part of the story. Investors now track clinical progress at least as closely as revenue. The company's Q3 2026 report mattered most because it delivered the long-awaited Phase 2 readout for ABCL635, its lead program for menopausal hot flashes. A positive result would validate AbCellera's in-house discovery platform and support a move into late-stage development, while a disappointing one would delay its evolution into a clinical-stage biotech. With a strengthened balance sheet and several earlier-stage programs advancing, this quarter offered a key test of the company's broader strategy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, AbCellera reported total revenue of $10.6 million, up from $9.0 million in the prior-year quarter. Net loss narrowed to $40.8 million, or $0.13 per basic and diluted share, compared with a net loss of $57.1 million, or $0.19 per share, a year earlier.
Results came in ahead of consensus. The reported loss of $0.13 per share beat the roughly $0.17 per-share loss analysts had expected, and revenue of $10.6 million exceeded the approximately $6.2 million estimate. Research and development (R&D) expense declined to $43.5 million from $55.0 million, while selling, general, and administrative (SG&A) expense fell to $13.6 million from $25.0 million a year earlier.
The clinical highlight was positive top-line Phase 2 data for ABCL635, which management described as combining strong efficacy with favorable tolerability, with no signs of the gastrointestinal toxicity seen with approved small-molecule competitors. The company expects to initiate late-stage development in 2027 and introduced ABCL992, a next-generation, longer-acting analog that entered IND-enabling (pre-clinical safety) activities during the quarter. Separately, AbCellera said it will not advance ABCL575 in atopic dermatitis following setbacks in the broader OX40 ligand class.
Market Reaction and Investor Sentiment
Heading into the report, sentiment around AbCellera was heavily tied to the ABCL635 Phase 2 readout rather than the financials alone. The positive efficacy and tolerability data, combined with a narrower-than-expected loss and a top-line revenue beat, framed the quarter as a validating moment for the company's internal pipeline strategy. The stock had already rallied substantially over the prior year, reflecting anticipation around the data. Investors are now focused on whether management can convert the Phase 2 result into a late-stage program and ultimately a competitive commercial product in the non-hormonal hot flash market.
Forward Outlook and Key Factors to Monitor
AbCellera's near-term narrative will be shaped by its execution on the ABCL635 program. Management plans to work with the U.S. Food and Drug Administration (FDA) on dose selection and expects to initiate late-stage development for menopausal vasomotor symptoms in 2027, with additional data through 12 weeks and from the open-label extension expected in early 2027.
The company is also expanding ABCL635 into hot flashes caused by hormone suppression linked to breast and prostate cancer treatment, with clinical trials targeted for 2027. Investors should watch for updates on ABCL992, the longer-acting follow-on candidate, as well as progress on other pipeline assets.
Financially, AbCellera retains a substantial liquidity cushion after its recent capital raise, which management frames as sufficient to advance its programs toward key value milestones. However, the company remains in a period of elevated R&D spending, and revenue from legacy partnerships is expected to stay modest as the internal pipeline matures. Key risks include clinical execution, regulatory feedback, and competitive dynamics in the hot flash market, where approved small-molecule treatments are already available. From what I see, monitoring these milestones closely will be essential.
Exploring Biotech Opportunities with AI Tools
When reviewing pipeline updates like those from AbCellera, I often turn to Tickeron’s AI Screener for a structured view of how the company fits within the broader biotech sector. It helps filter candidates using technical patterns, fundamentals, and performance metrics, which supports a more efficient research process without replacing deeper fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABCL in downward trend: price may drop because broke its higher Bollinger Band on October 28, 2026
ABCL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In 35 of the 41 cases the stock fell afterwards. This puts the odds of success at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 10-day moving average for ABCL crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ABCL entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 65 cases where ABCL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ABCL as a result. In 74 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
ABCL moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 207 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.296) is normal, around the industry mean (3.498). P/E Ratio (-22.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement